BioSyent Inc.
RX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 10.83% | 13.36% | 33.13% | 37.03% | 13.95% |
| Total Depreciation and Amortization | 169.57% | -36.33% | -31.08% | -32.92% | -32.03% |
| Total Amortization of Deferred Charges | -87.79% | 404.85% | 306.89% | 368.03% | 350.56% |
| Total Other Non-Cash Items | 76.93% | -609.55% | -1,682.45% | -649.76% | -380.76% |
| Change in Net Operating Assets | 160.62% | -112.31% | -1,199.51% | 122.99% | -17.48% |
| Cash from Operations | 67.72% | 1.66% | -53.16% | 74.59% | 0.30% |
| Capital Expenditure | 11.42% | -303.49% | -126.73% | -115.42% | -15.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 332.97% | 411.77% | 63.25% | 102.40% | 108.41% |
| Cash from Investing | 260.20% | 343.89% | 62.69% | 101.89% | 107.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -5.29% | -5.24% | -5.75% | -6.60% | -7.54% |
| Issuance of Common Stock | 274.29% | -- | -- | -- | 66.83% |
| Repurchase of Common Stock | -55.75% | 16.56% | 17.47% | -37.62% | -0.20% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -7.10% | -5.05% | -36.76% | -102.80% | -297.67% |
| Other Financing Activities | 13.45% | 12.87% | 12.21% | 11.72% | 11.40% |
| Cash from Financing | -32.38% | 11.39% | 5.86% | -45.59% | -27.60% |
| Foreign Exchange rate Adjustments | 115.29% | -253.23% | -190.76% | -161.54% | -174.92% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,577.84% | 105.92% | -20.25% | 105.39% | 101.41% |